CVRx Slashes Full-Year Outlook Despite Q2 Beat, Shares Near 52-Week Low
CVRX is trading near its 52-week low of $4.37 (0.7% above the low).
Summary
CVRx reported Q2 revenue of $15.71M, edging past the $15.55M consensus, but slashed its full-year revenue guidance to $58M–$60M from a prior implied range of roughly $62M–$64M. The cut reflects sales force disruptions and challenges with a large payer, overshadowing the modest beat. Q3 revenue is guided to $13.5M–$14.5M, well below the Q2 run rate, signaling a sharp deceleration. The stock is already trading near its 52-week low of $4.37, and this guidance reset removes any near-term recovery narrative. With a $50M ATM program already in place and a recent CFO departure, the operational and financial pressures are mounting. The next catalyst is the Q3 earnings report, where execution against this lowered bar will be critical.
At the time of this announcement, CVRX was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.6M. The 52-week trading range was $4.37 to $11.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.